Yung-Yeh Su
Overview
Explore the profile of Yung-Yeh Su including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
32
Citations
111
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Wang C, Hou Y, Hong Y, Tai Y, Shen C, Hou P, et al.
Mol Cancer
. 2025 Jan;
24(1):25.
PMID: 39825392
Background And Aims: Oncogenic KRAS mutations are present in approximately 90% of pancreatic ductal adenocarcinoma (PDAC). However, Kras mutation alone is insufficient to transform precancerous cells into metastatic PDAC. This...
2.
DAlessio A, Stefanini B, Blanter J, Adegbite B, Crowley F, Yip V, et al.
Lancet Oncol
. 2024 Oct;
25(11):1465-1475.
PMID: 39437804
Background: Neoadjuvant use of immune checkpoint inhibitors (ICIs) before liver resection results in pathological tumour regression in patients with hepatocellular carcinoma. We aimed to describe the characteristics of pathological responses...
3.
Liu T, Chen S, Rau K, Lu L, Lin P, Su Y, et al.
Liver Cancer
. 2024 Oct;
13(5):509-521.
PMID: 39435270
Introduction: The progression patterns, dispositions, and outcomes of patients with advanced hepatocellular carcinoma (HCC) who achieved durable responses with immunotherapy remain poorly characterized. Methods: Patients with advanced HCC who received...
4.
Shen Y, Liu T, Nicholas A, Soyama A, Yuan C, Chen T, et al.
J Clin Oncol
. 2024 Aug;
42(34):4060-4070.
PMID: 39197119
Purpose: Durable partial response (PR) and durable stable disease (SD) are often seen in patients with hepatocellular carcinoma (HCC) receiving atezolizumab plus bevacizumab (atezo-bev). This study investigates the outcome of...
5.
Wang S, Chiang P, Su Y, Yu Y, Chen Y, Chen T, et al.
Am J Surg Pathol
. 2024 Jul;
48(11):1425-1438.
PMID: 38979928
Burkitt lymphoma is characterized by high cell turnover and numerous cytoplasmic vacuoles that are demonstrated to be lipid droplets (LDs) decorated by adipophilin. By contrast, cytoplasmic vacuoles are variably observed...
6.
Tsai H, Yang S, Hsiao C, Kao H, Su Y, Shan Y, et al.
Oncologist
. 2024 Jun;
29(10):e1396-e1405.
PMID: 38902994
Background: Oxaliplatin- and fluoropyrimidine-based triplet regimens have demonstrated feasibility and efficacy in the treatment of upper gastrointestinal (UGI) cancers. Herein, we evaluate the feasibility and preliminary efficacy of biweekly nab-paclitaxel...
7.
Tang C, Yang S, Li C, Su Y, Chiu S, Bai L, et al.
Pancreatology
. 2024 Apr;
24(4):600-607.
PMID: 38565467
Background/objectives: Liposomal irinotecan plus 5-fluorouracil and leucovorin (nal-IRI + 5-FU/LV) provides survival benefits for metastatic pancreatic adenocarcinoma (mPDAC) refractory to gemcitabine-based treatment, mainly gemcitabine plus nab-paclitaxel (GA), in current practice....
8.
Hung Y, Wang H, Hsu S, Wang L, Tsai Y, Su Y, et al.
Am J Cancer Res
. 2024 Mar;
14(2):448-466.
PMID: 38455426
Perineural invasion and neurogenesis are frequently observed in pancreatic ductal adenocarcinoma (PDAC) and link to poor outcome. However, how neural factors affect PDAC prognosis and the underlying mechanism as well...
9.
Cheng S, Su Y, Chiang N, Wang C, Chao Y, Huang C, et al.
J Biomed Sci
. 2024 Feb;
31(1):21.
PMID: 38350919
Background: Cancer susceptibility germline mutations are associated with pancreatic ductal adenocarcinoma (PDAC). However, the hereditary status of PDAC and its impact on survival is largely unknown in the Asian population....
10.
Su Y, Chiang N, Chiu T, Huang C, Hsu S, Lin H, et al.
Biomed J
. 2024 Jan;
47(3):100696.
PMID: 38169173
Pancreatic cancer is a highly aggressive malignancy with a poor prognosis. Over the past decade, significant therapeutic advancements have improved the survival rates of patients with pancreatic cancer. One of...